Clearway Enterprise Announces Agreements for 1.6 GW Portfolio of Renewable Energy Assets

PRINCETON, N.J. and SAN FRANCISCO, Dec. 22, 2020 (GLOBE NEWSWIRE) — Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) (“CWEN”, “Company”) and its renewable development partner and parent company, Clearway Energy Group LLC (“CEG”), today announced agreements providing for CWEN’s co-investment in a 1,204 MW portfolio of renewable energy projects developed by CEG consisting of i) 1,012 MW from five geographically diversified wind, solar, and solar plus storage assets under development and ii) the 192 MW Rosamond Central solar project which is expected to commence operations by the end of the year. Additionally, the parties amended the existing partnership agreement for the 419 MW Mesquite Star wind project providing CWEN an additional 27.51% of the project’s cash flows after the first half of 2031.

Approximately 90% of the generation from the projects are contracted with a diverse group of primarily investment grade counterparties, including utilities and load serving entities, Fortune 500 corporations, commercial & industrial customers, and financial institutions, and the portfolio has a greater than 14-year blended average contract length. Subject to closing adjustments and the projects achieving certain milestones, CWEN expects to invest approximately $214 million in corporate capital by the end of 2022. Based on the current expected timing of the projects achieving COD, CWEN expects, before corporate financing costs, the asset CAFD contribution from the investments to be immaterial in 2021, approximately $9 million in 2022, and $20 million on a 5-year average basis beginning on January 1, 2023.

“Our commitment to invest in this portfolio of renewable energy and battery storage projects will add geographic and technological diversification at CWEN,” said Christopher Sotos, Clearway Energy, Inc.’s President and Chief Executive Officer. “We are pleased to achieve this important milestone in collaboration with our development partner and look forward to working together on future accretive portfolio investments.”

“We are thrilled to successfully complete our largest portfolio transaction to date with Clearway Energy, Inc.,” said Craig Cornelius, Chief Executive Officer at Clearway Energy Group LLC. “This geographically diverse 1.6 GW portfolio of wind, solar, and energy storage projects represents the economic opportunity of renewable energy in every corner of this country. Taken together, more than 2,500 American jobs will be created to build and operate these clean energy assets, which will go on to supply clean and low-cost power to hundreds of thousands of households and businesses across the United States. Today’s agreement with our investment partners will be pivotal in our continued ability to provide clean energy at the scale of our country’s demand while helping to deliver on investors’ growing interest in climate change solutions.”

The assets included in the portfolio are:

Asset Technology Type MW

1
CWEN Cash Allocation %

2
State Target Financial Closing
Additional Interest in Mesquite Star Wind 419 50% TX Closed
Rosamond Central Solar 192 50% CA Closed
Mesquite Sky Wind 345 50% TX 2H21
Black Rock Wind 110 50% WV 2H21
Waiawa Solar/Storage 36 50% HI 1H22
Mililani Solar/Storage 39 50% HI 1H22
Daggett Solar Solar/Storage 482 25% CA 2H22
           

Under the portfolio partnership agreements, CWEN will act as managing member. The remaining interest in the cash equity partnerships will be owned by Hannon Armstrong Sustainable Infrastructure Capital, Inc. (“Hannon Armstrong”) (NYSE: HASI), a leading investor in climate solutions.

On December 21, 2020, CWEN acquired its 50% cash equity interest in Rosamond Central for $23 million and completed the amendment for the additional interest in Mesquite Star. The Mesquite Sky wind farm in Texas and the Black Rock wind farm in West Virginia will commence construction in the coming weeks. Definitive agreements relating to the Daggett, Waiawa, and Mililani projects remain subject to certain conditions and the review and approval by CWEN’s Independent Directors.

CEG will serve as the long-term site operator and asset manager, ensuring continuity of performance and community engagement over the life of each project.

About Clearway Energy, Inc.

Clearway Energy, Inc. is a leading publicly-traded energy infrastructure investor focused on modern, sustainable and long-term contracted assets across North America. Clearway Energy’s environmentally-sound asset portfolio includes over 7,000 megawatts of wind, solar and natural gas-fired power generation facilities, as well as district energy systems. Through this diversified and contracted portfolio, Clearway Energy endeavors to provide its investors with stable and growing dividend income. Clearway Energy’s Class C and Class A common stock are traded on the New York Stock Exchange under the symbols CWEN and CWEN.A, respectively. Clearway Energy, Inc. is sponsored by its controlling investor Global Infrastructure Partners III (GIP), an independent infrastructure fund manager that invests in infrastructure and businesses in both OECD and select emerging market countries, through GIP’s portfolio company, Clearway Energy Group.

About Clearway Energy Group

Clearway Energy Group is leading the transition to a world powered by clean energy. Along with our public affiliate, Clearway Energy, Inc., we own and operate more than 5 gigawatts of wind, solar, and energy storage assets in 26 states, offsetting the equivalent of nearly 8.8 million metric tons of carbon emissions for our customers, and we are developing a pipeline of new renewable energy projects nationwide. With another 2.5 gigawatts of thermal energy systems and conventional power owned by our public affiliate, we’re also helping provide reliable and sustainable energy to thousands more customers across the country. Clearway Energy Group is headquartered in San Francisco, CA with offices in Carlsbad, CA; Scottsdale, AZ; Houston, TX; and Princeton, NJ. For more information, visit clearwayenergygroup.com.

_______________
1 MW capacity is subject to change prior to COD; excludes 395 MW/1,580 MWh of co-located storage assets at Daggett, Waiawa, and Mililani
2 The 50% cash allocation percentage for Mesquite Star represents CWEN’s total cash allocation percentage in the project inclusive of its September 1, 2020 acquisition of its initial interest in the project.

Safe Harbor Disclosure

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, and typically can be identified by the use of words such as “expect,” “estimate,” “anticipate,” “forecast,” “plan,” “outlook,” “believe” and similar terms.  Such forward-looking statements include, but are not limited to, statements regarding impacts related to COVID-19 or any other pandemic, the benefits of the relationship with Global Infrastructure Partners III (GIP) and GIP’s expertise, the Company’s future relationship and arrangements with GIP and Clearway Energy Group, as well as the Company’s Net Income, Adjusted EBITDA, Cash from Operating Activities, Cash Available for Distribution, the Company’s future revenues, income, indebtedness, capital structure, strategy, plans, expectations, objectives, projected financial performance and/or business results and other future events, and views of economic and market conditions.

Although Clearway Energy, Inc. believes that the expectations are reasonable, it can give no assurance that these expectations will prove to be correct, and actual results may vary materially. Factors that could cause actual results to differ materially from those contemplated above include, among others, impacts related to COVID-19 or any other pandemic, general economic conditions, hazards customary in the power industry, weather conditions, including wind and solar performance, competition in wholesale power markets, the volatility of energy and fuel prices, failure of customers to perform under contracts, changes in the wholesale power markets, changes in government regulations, the condition of capital markets generally, the Company’s ability to access capital markets, cyber terrorism and inadequate cybersecurity, the ability to engage in successful acquisitions activity, unanticipated outages at its generation facilities, adverse results in current and future litigation, failure to identify, execute or successfully implement acquisitions (including receipt of third party consents and regulatory approvals), the Company’s ability to enter into new contracts as existing contracts expire, risk relating to the Company’s relationships with GIP and Clearway Energy Group, the Company’s ability to acquire assets from GIP, Clearway Energy Group or third parties, the Company’s ability to close drop down transactions, and the Company’s ability to maintain and grow its quarterly dividends. Furthermore, any dividends are subject to available capital, market conditions, and compliance with associated laws and regulations.

Clearway Energy, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The Adjusted EBITDA and Cash Available for Distribution are estimates as of today’s date and are based on assumptions believed to be reasonable as of this date. Clearway Energy, Inc. expressly disclaims any current intention to update such guidance. The foregoing review of factors that could cause Clearway Energy, Inc.’s actual results to differ materially from those contemplated in the forward-looking statements included in this news release should be considered in connection with information regarding risks and uncertainties that may affect Clearway Energy, Inc.’s future results included in Clearway Energy, Inc.’s filings with the Securities and Exchange Commission at www.sec.gov. In addition, Clearway Energy, Inc. makes available free of charge at www.clearwayenergy.com copies of materials it files with, or furnishes to, the Securities Exchange Commission.

Contacts:

Investors:

Akil Marsh
[email protected]
609-608-1500
                    Media:

Zadie Oleksiw
[email protected]
202-836-5754 
     

Appendix Table A-1: Adjusted EBITDA and Cash Available for Distribution Reconciliation

The following table summarizes the calculation of Estimated Cash Available for Distribution and provides a reconciliation to Net Income/(Loss):

($ in millions)   2022 5-Year Average
2023-2027
Net Income   $ 21   $ 85  
Interest Expense, net   3   14  
Depreciation, Amortization, and ARO Expense   7   8  
Adjusted EBITDA   31   107  
Cash interest paid   (3 ) (14 )
Cash from Operating Activities   28   93  
Net distributions to non-controlling interest   (16 ) (48 )
Maintenance Capital Expenditures     (3 )
Principal amortization of indebtedness   (3 ) (22 )
Estimated Cash Available for Distribution   $ 9   $ 20  
               

Non-GAAP Financial Information


EBITDA and Adjusted EBITDA

EBITDA, Adjusted EBITDA, and Cash Available for Distribution (CAFD) are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. The presentation of non-GAAP financial measures should not be construed as an inference that Clearway Energy’s future results will be unaffected by unusual or non-recurring items.

EBITDA represents net income before interest (including loss on debt extinguishment), taxes, depreciation and amortization. EBITDA is presented because Clearway Energy considers it an important supplemental measure of its performance and believes debt and equity holders frequently use EBITDA to analyze operating performance and debt service capacity. EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are:

  • EBITDA does not reflect cash expenditures, or future requirements for capital expenditures, or contractual commitments;
  • EBITDA does not reflect changes in, or cash requirements for, working capital needs;
  • EBITDA does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements; and
  • Other companies in this industry may calculate EBITDA differently than Clearway Energy does, limiting its usefulness as a comparative measure.

Because of these limitations, EBITDA should not be considered as a measure of discretionary cash available to use to invest in the growth of Clearway Energy’s business. Clearway Energy compensates for these limitations by relying primarily on our GAAP results and using EBITDA and Adjusted EBITDA only supplementally. See the statements of cash flow included in the financial statements that are a part of this news release.

Adjusted EBITDA is presented as a further supplemental measure of operating performance. Adjusted EBITDA represents EBITDA adjusted for mark-to-market gains or losses, non-cash equity compensation expense, asset write offs and impairments; and factors which we do not consider indicative of future operating performance such as transition and integration related costs. The reader is encouraged to evaluate each adjustment and the reasons Clearway Energy considers it appropriate for supplemental analysis. As an analytical tool, Adjusted EBITDA is subject to all of the limitations applicable to EBITDA. In addition, in evaluating Adjusted EBITDA, the reader should be aware that in the future Clearway Energy may incur expenses similar to the adjustments in this news release.

Management believes Adjusted EBITDA is useful to investors and other users of our financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. This measure is widely used by investors to measure a company’s operating performance without regard to items such as interest expense, taxes, depreciation and amortization, which can vary substantially from company to company depending upon accounting methods and book value of assets, capital structure and the method by which assets were acquired.

Additionally, Management believes that investors commonly adjust EBITDA information to eliminate the effect of restructuring and other expenses, which vary widely from company to company and impair comparability. As we define it, Adjusted EBITDA represents EBITDA adjusted for the effects of impairment losses, gains or losses on sales, non-cash equity compensation expense, dispositions or retirements of assets, any mark-to-market gains or losses from accounting for derivatives, adjustments to exclude gains or losses on the repurchase, modification or extinguishment of debt, and any extraordinary, unusual or non-recurring items plus adjustments to reflect the Adjusted EBITDA from our unconsolidated investments. We adjust for these items in our Adjusted EBITDA as our management believes that these items would distort their ability to efficiently view and assess our core operating trends.

In summary, our management uses Adjusted EBITDA as a measure of operating performance to assist in comparing performance from period to period on a consistent basis and to readily view operating trends, as a measure for planning and forecasting overall expectations and for evaluating actual results against such expectations, and in communications with our Board of Directors, shareholders, creditors, analysts and investors concerning our financial performance.


Cash Available for Distribution

A non-GAAP measure, Cash Available for Distribution is defined as of September 30, 2020 as Adjusted EBITDA plus cash distributions/return of investment from unconsolidated affiliates, adjustments to reflect CAFD generated by unconsolidated investments that were not able to distribute project dividends prior to PG&E’s emergence from bankruptcy on July 1, 2020 and subsequent release post-bankruptcy, cash receipts from notes receivable, cash distributions from noncontrolling interests, adjustments to reflect sales-type lease cash payments, less cash distributions to noncontrolling interests, maintenance capital expenditures, pro-rata Adjusted EBITDA from unconsolidated affiliates, cash interest paid, income taxes paid, principal amortization of indebtedness, Walnut Creek investment payments, changes in prepaid and accrued capacity payments, and adjusted for development expenses. Management believes CAFD is a relevant supplemental measure of the Company’s ability to earn and distribute cash returns to investors.

We believe CAFD is useful to investors in evaluating our operating performance because securities analysts and other interested parties use such calculations as a measure of our ability to make quarterly distributions. In addition, CAFD is used by our management team for determining future acquisitions and managing our growth. The GAAP measure most directly comparable to CAFD is cash provided by operating activities.

However, CAFD has limitations as an analytical tool because it does not include changes in operating assets and liabilities and excludes the effect of certain other cash flow items, all of which could have a material effect on our financial condition and results from operations. CAFD is a non-GAAP measure and should not be considered an alternative to cash provided by operating activities or any other performance or liquidity measure determined in accordance with GAAP, nor is it indicative of funds available to fund our cash needs. In addition, our calculations of CAFD are not necessarily comparable to CAFD as calculated by other companies. Investors should not rely on these measures as a substitute for any GAAP measure, including cash provided by operating activities.



Translate Bio Announces Departure of Chief Financial Officer

LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Company’s Chief Financial Officer (CFO), is departing the Company for personal reasons. Mr. Schroer’s departure will be effective by year-end 2020. Robert Prentiss, Translate Bio’s Vice President and Corporate Controller since 2017, will serve as Principal Accounting Officer and report directly to the Company’s Chief Executive Officer, Ronald Renaud, on an interim basis while a formal search process to appoint a new CFO is conducted.

“John has played a valuable role on the leadership team as we transitioned to a public company, established a major strategic partnership for infectious disease vaccines and advanced our manufacturing activities and mRNA therapeutic programs,” said Ronald Renaud, Chief Executive Officer of Translate Bio. “We respect and support John’s decision to return to the Bay Area, and we thank him for his contributions and wish him every success in the future.”

About Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio believes that mRNA can be delivered to target tissues via multiple routes of administration and, consequently, its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Investor Relations Media Relations
   
Teri Dahlman Maura Gavaghan
   
Tel.: +1 (617) 817-8655 Tel: +1 (617) 233-1154
   
[email protected] [email protected]

 



StoneCastle Financial Corp. Releases Month End Estimated Net Asset Value as of November 2020

DENVER, Dec. 22, 2020 (GLOBE NEWSWIRE) — StoneCastle Financial Corp., (NASDAQ:BANX) (“StoneCastle Financial” or the “Company”), today announced that the Company’s unaudited estimated Net Asset Value (“NAV”) as of November 30, 2020 was $21.57. The NAV was up $0.55 or approximately 3% as compared to the prior month-end.

This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended November 30, 2020. We advise you that our NAV per share for the fourth quarter ending December 31, 2020 may differ materially from this NAV, which is given only as of November 30, 2020.

About StoneCastle Financial Corp.

StoneCastle Financial is an SEC registered non-diversified, closed-end investment company listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide stockholders with current income and, to a lesser extent, capital appreciation. StoneCastle Financial is managed by StoneCastle-ArrowMark Asset Management, LLC. To learn more, visit www.stonecastle-financial.com.

Disclaimer and Risk Factors:

There is no assurance that StoneCastle Financial will achieve its investment objective. StoneCastle Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of StoneCastle Financial may not be appropriate for all investors. Investors should review and consider carefully StoneCastle Financial’s investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC’s website at www.sec.gov and on the Company’s website at www.stonecastle-financial.com.

Contact:

Julie Muraco
212-468-5441



REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million

– Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314

PR Newswire

ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it has entered into an agreement to sell a portion of the royalty rights due to REGENXBIO from Novartis Gene Therapies from the net sales of Zolgensma® to entities managed by Healthcare Royalty Management, LLC (HCR) for a gross purchase price of $200 million. This transaction provides immediate, non-dilutive capital to REGENXBIO for continued innovation in the development of potential breakthrough gene therapies for patients and completion of its internal manufacturing capabilities.

“Our rapidly advancing internal pipeline has enabled us to broaden the potential impact that gene therapies can have for patients in both large and orphan indications. This agreement with HCR provides us with significant additional non-dilutive funding to continue our momentum in the clinic focused on RGX-314 and our rare neurodegenerative disease platform, including RGX-121, as well as the opportunity to develop new innovations for patients in other disease areas,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “The capital will continue to support our pipeline transition into late-stage development and the establishment of internal manufacturing facilities with 2,000 liter scale using our platform suspension cell culture process for emerging commercial requirements, so that we can continue to work towards our mission of improving the lives of patients.”

Under the terms of the agreement, REGENXBIO will receive $200 million from HCR as an upfront payment in exchange for REGENXBIO’s royalty rights from the net sales of Zolgensma, including a portion of the royalties received in the fourth quarter of 2020, up to 1.3 times the purchase price until November 7, 2024 or, if such cap is not met by November 7, 2024, up to 1.5 times the purchase price thereafter. If either cap is met, the royalty rights would revert to REGENXBIO.

Zolgensma is currently approved for the treatment of Spinal Muscular Atrophy (SMA) in the United States, Japan, Europe, Brazil and Canada. Novartis is also pursuing registration in additional countries.

“Zolgensma is a truly innovative treatment for SMA based on REGENXBIO’s NAV technology which we believe demonstrates the transformational impact that gene therapy can offer patients. We are pleased to partner with REGENXBIO in this royalty agreement to recognize the value of this therapy, and to enable the further development of their internal pipeline of new gene therapies for patients in need,” said Clarke B. Futch, Managing Partner & Chairman of HCR.

Morgan Stanley & Co. LLC served as sole structuring agent and Covington & Burling LLP served as counsel to REGENXBIO.  Morgan Lewis & Bockius LLP acted as counsel to HCR.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

About HCR

HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets. HCR has raised $5.7 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston and London  For more information, visit www.healthcareroyalty.com

Forward-Looking Statements

This press release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would” or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO’s clinical trials, future operations and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO’s expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, the impact of the COVID-19 pandemic or similar public health crises on REGENXBIO’s business, and other factors, many of which are beyond the control of REGENXBIO. Refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of REGENXBIO’s Annual Report on Form 10-K for the year ended December 31, 2019, and comparable “risk factors” sections of REGENXBIO’s Quarterly Reports on Form 10-Q and other filings, which have been filed with the U.S. Securities and Exchange Commission (SEC) and are available on the SEC’s website at www.sec.gov. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Zolgensma® is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.

Contacts:

Tricia Truehart

Investor Relations and Corporate Communications
347-926-7709
[email protected]

Investors:
Eleanor Barisser, 212-600-1902
[email protected]

Media:
David Rosen, 212-600-1902
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-agreement-to-monetize-portion-of-zolgensma-royalties-for-200-million-301197818.html

SOURCE REGENXBIO Inc.

Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences (Nasdaq: NBIX) that it has placed a clinical hold on the RESTORE-1 clinical trial of NBIb-1817 (VY-AADC). As previously announced, trial sites participating in RESTORE-1 had not been screening, enrolling or dosing patients as a result of the COVID-19 pandemic and more recently, as a result of the independent Data Safety Monitoring Board (DSMB)’s request to pause dosing pending its review of additional data. The DSMB has requested additional patient level data from the trial and now plans to review these data in early 2021. The clinical hold follows the submission by Neurocrine Biosciences of an IND Safety Report related to the observation of MRI abnormalities in some RESTORE-1 study participants. The clinical implications of this observation are currently unknown and are being evaluated.

RESTORE-1 is a Phase 2 clinical trial of NBIb-1817 (VY-AADC), an intracerebral AAV-based investigational gene therapy, in development for the treatment of Parkinson’s disease. The RESTORE-1 DSMB has been informed of the clinical hold, as have the study investigators and central and local ethics committees. Neurocrine Biosciences and Voyager will work closely with the FDA and the DSMB to determine the next steps for the RESTORE-1 clinical trial.


About Parkinson’s Disease and NBIb-1817 (VY-AADC)


Parkinson’s disease is a chronic, progressive, and debilitating neurodegenerative disease that affects approximately one million people in the U.S. and ten million people worldwide. It is characterized by a loss of dopamine and neuronal degeneration with a concomitant loss of the aromatic L-amino acid decarboxylase (AADC) enzyme required to synthesize dopamine in the brain, leading to associated impairment in motor, neuropsychiatric, and autonomic functions. Dopamine is a chemical “messenger” that is produced in the brain and is involved in the control of movement. It is made when AADC converts the chemical levodopa to dopamine. As Parkinson’s disease progresses, there is less AADC enzyme in parts of the brain where levodopa is converted to dopamine.

NBIb-1817 (VY-AADC) is an investigational recombinant adeno-associated viral (AAV) serotype 2 vector encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine. NBIb-1817 (VY-AADC) is administered into the brain using intraoperative monitoring with magnetic resonance imaging (MRI)-facilitated targeted delivery.


About Voyager Therapeutics


Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information on Voyager Therapeutics, please visit the company’s website at www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Voyager Therapeutics® is a registered trademark of Voyager Therapeutics, Inc.


Voyager Therapeutics Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the ability of Neurocrine and Voyager to gather additional information to further characterize the safety profile of NBIb-1817 (VY-AADC) and to work with the FDA to determine the next steps for the RESTORE-1 clinical trial.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the ability of Neurocrine and Voyager to complete their evaluation and to meet the information requests of, and to resolve questions raised by, the FDA required to bring an end to the clinical hold on the RESTORE-1 clinical trial. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

Voyager Therapeutics

Investors:        
[email protected]

Media:        
Sheryl Seapy
W2Opure
949-903-4750
[email protected]

 



Qualys Researchers Identify 7+ Million Vulnerabilities Associated with SolarWinds/FireEye Breach by Analyzing Anonymized Vulnerabilities across Worldwide Customer Base

Qualys offers free 60-day integrated Vulnerability Management, Detection and Response service to help organizations quickly assess devices impacted by SolarWinds Orion vulnerabilities, SUNBURST Trojan detections, and FireEye Red Team tools, and to remediate and track results via dynamic dashboards

PR Newswire

FOSTER CITY, Calif., Dec. 22, 2020 /PRNewswire/ — Qualys, Inc. (NASDAQ: QLYS), a pioneer and leading provider of cloud-based security and compliance solutions, today announced its research team, using the Qualys Cloud Platform, has identified 7.54 million vulnerabilities related to FireEye Red Team assessment tools and compromised versions of SolarWinds Orion, tracked as Solorigate or SUNBURST, across its 15,700-member customer base.

Of the vulnerabilities identified, researchers noted that across 5.29 million unique assets most are related to the FireEye Red Team tools. These findings highlight the scope of the potential attack surface if these tools are misused. The research team further identified that 99.84% of the 7+ million vulnerability instances are from eight vulnerabilities in Microsoft software that have patches available.

To help mitigate risk and exposure from this breach, Qualys is providing IT and security teams free 60-day access to its integrated Vulnerability Management, Detection and Response service, which leverages the power of the Qualys Cloud Platform.

More information can be found on the Qualys advisory blog at qualys.com/solarwinds-fireeye-advisory-blog-post.

“The Qualys free solution provides much-needed visibility and response in a single app that many need at a time when IT and security organizations around the world are scrambling to shore up their systems,” said Frank Dickson, program vice president, Security and Trust at IDC. “Qualys’ solution draws from its native security and compliance platform to deliver vulnerability management, detection and response, the ability to detect malware, and the integrity of files. It is great solution, easy to use and deploy, and it’s hard to beat as it is free.”

“The scope of this nation-state attack is massive, as overnight a widely used and trusted piece of software turned into known malware,” said Sumedh Thakar, president and chief product officer at Qualys. “Since its discovery, Qualys teams have been actively researching the issue and helping customers assess their environments. The good news is that nearly all of the CVE’s are patchable, and we’ve made this solution available to the industry so they can immediately work to protect themselves from being exploited by these vulnerabilities.”

Qualys is offering a fully functional license free for 60 days. The license enables full situational awareness, detection, and remediation to reduce risk and exposure from the SolarWinds and FireEye breaches. It includes:

  • Real-time, up-to-date inventory and automated organization of all assets, applications, and services running across the hybrid-IT environment
  • Continuous view of all critical vulnerabilities and their prioritization based on real-time threat indicators and attack surface
  • Automatic correlation of applicable patches for identified vulnerabilities
  • Patch deployment via Qualys Cloud Agents with zero impact to VPN bandwidth
  • Security configuration hygiene assessment to apply as compensating controls to reduce vulnerability risk
  • Unified dashboards that consolidate all insights for management visualization via a single pane of glass

“As our teams assessed the very sophisticated SolarWinds / FireEye nation-state attack, we realized that we could help the industry through our very powerful unified Cloud Platform. The integrated security solution provides real-time visibility across the entire global and hybrid IT environment allowing it to detect and prioritize critical vulnerabilities, identify malware and effectively respond all from one single pane of glass,” said Philippe Courtot, chairman and CEO of Qualys.

To sign up for the free 60-day service visit www.qualys.com/solarhack/.

Qualys Webinar
Please join us on Thursday, Dec. 24, for a webcast with the Qualys vulnerability and malware research team to discuss the recent Solorigate/SUNBURST attack and get more information on using Qualys’ free 60-day service to mitigate risk and exposure from the breach. Register at qualys.com/solarwinds-fireeye-webcast.

Additional Resources 

About Qualys 
Qualys, Inc. (NASDAQ: QLYS) is a pioneer and leading provider of cloud-based security and compliance solutions with over 15,700 active customers in more than 130 countries, including a majority of each of the Forbes Global 100 and Fortune 100. Qualys helps organizations streamline and consolidate their security and compliance solutions in a single platform and build security into digital transformation initiatives for greater agility, better business outcomes, and substantial cost savings.

The Qualys Cloud Platform and its integrated Cloud Apps deliver businesses critical security intelligence continuously, enabling them to automate the full spectrum of auditing, compliance, and protection for IT systems and web applications across on premises, endpoints, cloud, containers, and mobile environments. Founded in 1999 as one of the first SaaS security companies, Qualys has established strategic partnerships with leading cloud providers like Amazon Web Services, Microsoft Azure and the Google Cloud Platform, and managed service providers and consulting organizations including Accenture, BT, Cognizant Technology Solutions, Deutsche Telekom, DXC Technology, Fujitsu, HCL Technologies, IBM, Infosys, NTT, Optiv, SecureWorks, Tata Communications, Verizon and Wipro. The company is also a founding member of the Cloud Security Alliance. For more information, please visit www.qualys.com.

Qualys and the Qualys logo are proprietary trademarks of Qualys, Inc. All other products or names may be trademarks of their respective companies.

Media Contact:
 

Tami Casey, Qualys 
(650) 801-6196 
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/qualys-researchers-identify-7-million-vulnerabilities-associated-with-solarwindsfireeye-breach-by-analyzing-anonymized-vulnerabilities-across-worldwide-customer-base-301197812.html

SOURCE Qualys, Inc.

Rexford Industrial Announces Appointment Of Debra Morris To Board Of Directors

PR Newswire

LOS ANGELES, Dec. 22, 2020 /PRNewswire/ — Rexford Industrial Realty, Inc. (the “Company” or “Rexford Industrial”) (NYSE: REXR), a real estate investment trust focused on creating value by investing in and operating industrial properties located in Southern California infill markets, today announced that Debra L. Morris has been appointed as an independent director to the Company’s Board of Directors effective December 31, 2020. 

Debra L. Morris is currently Executive Vice President, Chief Financial Officer of Apria Healthcare, a leading provider of integrated home healthcare equipment and related services in the United States, a role in which she has served since March 2013. Prior to joining Apria, Ms. Morris served as Chief Financial Officer—Americas for SITEL Worldwide Corporation, a global leader in business processing outsourcing, from 2010 to 2013. Prior to that she served with Tatum LLC, a national executive services firm, from 2004 to 2010 where she held roles as Partner and Director during her tenure. From 1999 to 2002 she was Chief Financial Officer of Caliber Collision Centers. Ms. Morris spent the earlier part of her career in various roles with CB Richard Ellis, including as Executive Vice President—Global Marketing and Integration and Executive Vice President—Global Chief Accounting Officer. She currently serves on the board and chairs the Audit Committee of ALC Schools, a provider of alternative student transportation for school districts nationwide.

“We are very pleased to welcome Debra to Rexford Industrial’s Board of Directors,” stated Tyler Rose, Director and Chairperson of the Company’s Nominating and Corporate Governance Committee. “Debra will bring significant experience in corporate finance and real estate, and we expect the Board will benefit from her engagement and counsel as we continue to grow our innovative company and drive superior shareholder returns by investing in the infill Southern California industrial market.”

In connection with Rexford Industrial’s ongoing pursuit of enhanced board diversity and refreshment, Steven C. Good will be retiring from the Board concurrent with Ms. Morris’ appointment.  Mr. Good’s decision to resign was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. 

“Having served on our Board since our IPO in 2013, we are very grateful to Steven for his many years of very valuable service to the Company and we wish him all the very best. We are excited for Debra to join our Board as we continue to add new perspectives,” said Richard S. Ziman, Chairman of Rexford Industrial.  Rexford Industrial’s Co-CEOs, Michael Frankel and Howard Schwimmer, added “We thank Steven for his dedication and time-tested support of the Company.  At the same time, we are pleased to welcome Debra as a new independent director as we embark upon our next stage of growth.”

Ms. Morris will serve on the Company’s Audit and Compensation Committees. Tyler Rose will be appointed Chairperson of the Audit committee and Diana Ingram will be appointed the Company’s Chairperson of the Nominating and Governance Committee.

About Rexford Industrial

Rexford Industrial, a real estate investment trust focused on creating value by investing in and operating industrial properties throughout Southern California infill markets, owns 243 properties with approximately 31.0 million rentable square feet and manages an additional 20 properties with approximately 1.0 million rentable square feet.

For additional information, visit www.rexfordindustrial.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect the Company’s good faith beliefs, assumptions and expectations, they are not guarantees of future performance. For a further discussion of these and other factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the reports and other filings by the Company with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Current Report on Form 8-K filed with the SEC on or about the date of this press release. The Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.

Contact:
Investor Relations:
Stephen Swett
424 256 2153 ext. 401
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/rexford-industrial-announces-appointment-of-debra-morris-to-board-of-directors-301197753.html

SOURCE Rexford Industrial Realty, Inc.

E2open and CC Neuberger Principal Holdings I Announce Additional $175 Million Fully Committed Common Stock PIPE at $10 per share

Leading End-to-End and Cloud-Based Supply Chain Management SaaS Platform Positioned for Continued Growth and Value Creation

Fully Committed Common Stock PIPE Led by Highly-Reputable, Concentrated Long-Only and Long-Term Investor

PR Newswire

AUSTIN, Texas, Dec. 22, 2020 /PRNewswire/ — E2open (the “Company”), a leading network-based provider of 100% cloud-based, end-to-end supply chain management software, and CC Neuberger Principal Holdings I (NYSE: PCPL), a publicly traded special purpose acquisition company, today provided an update on activities as they move forward with their planned combination, including the announcement of an additional $175 million fully-committed PIPE at $10 per share led by a very reputable and highly-concentrated long-only investor.  The PIPE also includes support from one of the largest prior fundamental investors in the transaction.

The additional PIPE will result in a total equity investment of $1.3 billion raised in the transaction, which will be used to pay down existing debt, purchase a portion of the equity owned by existing E2open owners and conservatively capitalize the Company’s balance sheet. At closing, it is expected that the company will have a net leverage ratio of approximately 2.7x its fiscal year 2022 Pro Forma Adjusted EBITDA of $121 million (February fiscal year end).

“We are excited to add another blue-chip, long-term partner to our investor base.  This investment is a recognition of the tremendous opportunity in front of us and unlocks further capacity for investment in organic growth and a robust pipeline of acquisition opportunities to drive shareholder value creation,” said Michael Farlekas, Chief Executive Officer of E2open.

CC Neuberger Principal Holdings I has set a record date of December 23, 2020, and the transaction is expected to close early in the first calendar quarter of 2021.  Management expects to provide a preliminary update of the unaudited financial results from its third fiscal quarter of 2021 in January.

About E2open

At E2open, we’re creating a more connected, intelligent supply chain. It starts with sensing and responding to real-time demand, supply and delivery constraints. Bringing together data from clients, distribution channels, suppliers, contract manufacturers and logistics partners, our collaborative and agile supply chain platform enables companies to use data in real time, with artificial intelligence and machine learning to drive smarter decisions. All this complex information is delivered in a single view that encompasses your demand, supply and logistics ecosystems. E2open is changing everything. Demand. Supply. Delivered.

Visit www.e2open.com.   

E2open, the E2open logo, Harmony and INTTRA are registered trademarks of E2open, LLC. All other trademarks, registered trademarks and service marks are the property of their respective owners.   

About CC Neuberger Principal Holdings I

CC Neuberger Principal Holdings I is a special purpose acquisition company that completed its initial public offering in April 2020, raising $414 million in proceeds. Formed and led by Chinh E. Chu, Douglas Newton, Charles Kantor and other senior professionals of CC Capital and Neuberger Berman, CC Neuberger Principal Holdings I is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. CC Neuberger Principal Holdings I’s Class A common shares, units, and warrants trade on the NYSE under the symbols “PCPL” and “PCPL WS,” respectively.

Additional Information

In connection with the proposed business combination, including the domestication of CC Neuberger Principal Holdings I as a Delaware corporation, CC Neuberger Principal Holdings I has filed with the SEC a registration statement on Form S-4 containing a draft proxy statement and a draft prospectus of CC Neuberger Principal Holdings I, and after the registration statement is declared effective, CC Neuberger Principal Holdings I will mail a definitive proxy statement/prospectus relating to the proposed business combination to its shareholders. This announcement does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. CC Neuberger Principal Holdings I’s shareholders and other interested persons are advised to read the draft proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about CC Neuberger Principal Holdings I, the Company and the business combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to shareholders of CC Neuberger Principal Holdings I as of a record date to be established for voting on the proposed business combination. Shareholders are able to obtain copies of the draft proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: CC Neuberger Principal Holdings I, 200 Park Avenue, New York, NY 10166.

Participants in the Solicitation

CC Neuberger Principal Holdings I and its directors and executive officers may be deemed participants in the solicitation of proxies from CC Neuberger Principal Holdings I’s shareholders with respect to the proposed business combination. A list of the names of those directors and executive officers and a description of their interests in CC Neuberger Principal Holdings I is contained in CC Neuberger Principal Holdings I’s final prospectus related to its initial public offering dated April 23, 2020, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a request to CC Neuberger Principal Holdings I, 200 Park Avenue, New York, NY 10166. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed business combination when available.

The Company and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of CC Neuberger Principal Holdings I in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination is included in the draft proxy statement for the proposed business combination.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of CC Neuberger Principal Holdings I or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or CC Neuberger Principal Holdings I’s or the Company’s future financial or operating performance. For example, projections of future growth, financial performance, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by CC Neuberger Principal Holdings I and its management, and the Company and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the business combination; (2) the outcome of any legal proceedings that may be instituted against CC Neuberger Principal Holdings I, the combined company or others following the announcement of the business combination and any definitive agreements with respect thereto; (3) the inability to complete the business combination due to the failure to obtain approval of the shareholders of CC Neuberger Principal Holdings I, to obtain financing to complete the business combination or to satisfy other conditions to closing; (4) changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the business combination; (5) the ability to meet stock exchange listing standards following the consummation of the business combination; (6) the risk that the business combination disrupts current plans and operations of the Company as a result of the announcement and consummation of the business combination; (7) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the business combination; (9) changes in applicable laws or regulations; (10) the possibility that the Company or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the Company’s estimates of expenses and profitability; and (12) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in CC Neuberger Principal Holdings I’s final prospectus relating to its initial public offering dated April 23, 2020.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither CC Neuberger Principal Holdings I nor the Company undertakes any duty to update these forward-looking statements.

The closing of the additional PIPE is conditioned upon the closing of the proposed business combination.  The intended uses of the cash proceeds of the transaction assumes no redemptions by shareholders of CC Neuberger Principal Holdings I.

Contacts


Investor Contacts

Michael Bowen

ICR, Inc.
[email protected]
203-682-8299

Marc P. Griffin

ICR, Inc.
[email protected]
646-277-1290


Media Contacts

CC Neuberger Principal Holdings I

CC Capital

Jonathan Keehner / Julie Oakes / Kate Thompson
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Neuberger Berman

Alex Samuelson

[email protected]

(212) 476-5392

Cision View original content:http://www.prnewswire.com/news-releases/e2open-and-cc-neuberger-principal-holdings-i-announce-additional-175-million-fully-committed-common-stock-pipe-at-10-per-share-301197793.html

SOURCE CC Neuberger Principal Holdings I

Markem-Imaje Launches Rental Program

PR Newswire

DOWNERS GROVE, Ill., Dec. 22, 2020 /PRNewswire/ — Markem-Imaje, part of Dover (NYSE: DOV), is launching Confidence 360, a rental program which gives manufacturers a cost-effective way of benefitting from high-quality, turnkey coding solutions. Scalable and customizable, Confidence 360 covers all hardware, software and consumables needed to code products, cases and pallets, at a fixed, periodic fee, with no upfront cost.

The new program gives manufacturers the flexibility to build a coding solution that meets their particular production challenges and business goals while adapting easily to changing market demands. Users can choose to add or upgrade equipment when needed, include software for automation, and make certain they have the right consumables at the right time to ensure high-quality prints with predictable costs and simplified operations.

Confidence 360 consists of three elements: Coding 360, Packaging Intelligence 360, and Supplies 360. Coding 360 is the heart of the program and offers flexible equipment rentals, while Packaging Intelligence 360 and Supplies 360, both of which are optional, include advanced production control software and convenient sourcing of consumables.

Coding 360 offers easy access to the market’s most comprehensive range of printers and coders. By providing manufacturers with equipment replacements and upgrades every three to five years, users can rest assured that they have the most cutting-edge technology.

Packaging Intelligence 360 lets manufacturers add digital solutions to their printers and coders to improve productivity and accuracy. Markem-Imaje offers software, cameras and software support agreements, allowing digital control of data, coding and packaging.

Applications available under Packaging Intelligence 360 include product tracking, promotional coding, serialization, line management, overall equipment effectiveness, pallet tracking, coding integrity and packaging integrity. The result is improved line efficiency, brand protection and compliance, with minimum waste and errors.

Supplies 360 makes it easy to get genuine Markem-Imaje inks and other consumables, avoiding alternatives that are not calibrated for the selected equipment. This enables business continuity and reduced ownership costs by ensuring plants are using the most cost-efficient and effective consumables to maximize printer availability and performance.

“Modular and flexible, Confidence 360 helps manufacturers find the ideal balance between quality and cost, maximizing their investment returns. It also gives them peace of mind and ensures they can easily evolve their coding solution as their needs change,” said Viktor Hermansson, Global Marketing and Communications Manager, Markem-Imaje. “Having received overwhelmingly positive from customers following a trial in select European countries, we decided to make this program available globally. We are excited for more manufacturers to be able to experience the many benefits this new program has to offer.”

Budgeting is made easier with a fixed monthly or quarterly payment, removing the need for a single upfront investment and turning a capital cost into a more manageable operational expense. This helps achieve a faster return on investment and releases funds for more important business priorities. It also allows manufacturers to get the solutions they need without being concerned about the full purchase price.

As part of the program, Markem-Imaje provides certified installations, user training and operator assistance with the option of premium services such as preventive maintenance visits, parts and a 24/7 helpdesk (subject to local availability).

About Markem-Imaje:

Markem-Imaje, a wholly-owned subsidiary of the US-based Dover Corporation is a trusted world manufacturer of product identification and traceability solutions, offering a full line of reliable and innovative inkjet, thermal transfer, laser, and print and apply label systems. Markem-Imaje provides global reach to over 50,000 customers with 30 subsidiaries, 6 technology centers, several equipment repair centers and manufacturing plants with the most comprehensive marking and coding portfolio available in the marketplace. Visit www.markem-imaje.com for further information.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of approximately $7 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Fueling Solutions, Imaging & Identification, Pumps & Process Solutions and Refrigeration & Food Equipment. Dover combines global scale, operational agility, world-class engineering capability and customer intimacy to lead the markets we serve. Recognized for our entrepreneurial approach for over 60 years, our team of over 23,000 employees takes an ownership mindset, collaborating with customers to redefine what’s possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under “DOV.” Additional information is available at dovercorporation.com.

Markem-Imaje Contact:

Christine Bonnet

33 (0)4 75 75 55 16
[email protected]

Dover Media Contact:
Adrian Sakowicz, VP, Communications    
(630) 743-5039    
[email protected]

Dover Investor Contact:
Andrey Galiuk, VP, Corporate Development and Investor Relations   
(630) 743-5131   
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/markem-imaje-launches-rental-program-301197694.html

SOURCE Dover

Ooma to Attend Needham Virtual Growth Conference

Ooma to Attend Needham Virtual Growth Conference

SUNNYVALE, Calif.–(BUSINESS WIRE)–
Ooma, Inc. (NYSE: OOMA), a smart communications platform for businesses and consumers, today announced the following conference participation:

What: 23rd Annual Needham Virtual Growth Conference, presentation and investor meetings, January 15, 2021

When: Presentation (fireside chat) 2:00 p.m. until 2:40 p.m. ET on January 15

Who: Ooma CEO Eric Stang and Ooma CFO Ravi Narula

Where: Virtual/webcast

The presentation will be webcast as live audio and available for replay for 180 days from the Events & Presentation page of the Investor Relations section of Ooma’s website, https://investors.ooma.com/investors/events-and-presentations/.

In addition to the presentation, Messrs. Stang and Narula will also be holding virtual meetings with investors; interested parties should contact their Needham & Company sales representative.

About Ooma

Ooma (NYSE: OOMA) creates powerful connected experiences for businesses and consumers, delivered from its smart cloud-based SaaS platform. For businesses of all sizes, Ooma provides advanced voice and collaboration features that are flexible and scalable. For consumers, Ooma’s residential phone service provides PureVoice HD voice quality, advanced functionality and integration with mobile devices. Ooma’s innovative smart security solution delivers a range of wireless security sensors that make it easy for anyone to protect their home. Learn more at www.ooma.com or www.ooma.ca in Canada.

INVESTOR CONTACT:

Matthew S. Robison

Director of IR and Corporate Development

Ooma, Inc.

[email protected]

(650) 300-1480

MEDIA CONTACT:

Mike Langberg

Director of Corporate Communications

Ooma, Inc.

[email protected]

(650) 566-6693

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Mobile/Wireless Security Telecommunications Software Networks Internet Data Management VoIP

MEDIA:

Logo
Logo